Cytokinetics, Incorporated
CYTK · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $7 | $4 | $5 | $6 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $1 | $1 | $1 | $1 |
| Enterprise Value | $7 | $5 | $5 | $6 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -97.1% | 4,128.6% | -90.7% | – |
| Gross Profit | -$0 | $0 | -$0 | -$0 |
| % Margin | -38.4% | 96.6% | -6,223.1% | -453.1% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -14,317% | -161.5% | -8,621.3% | -738.7% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -15,815% | -201.2% | -10,220.1% | -886.3% |
| EPS Diluted | -2.55 | -1.12 | -1.36 | -1.27 |
| % Growth | -127.7% | 17.6% | -7.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |